BR0309990A - Processo para produzir um hidrato de um sal de adição de ácido de um composto, hidrato de um sal de adição de ácido de um composto, composição farmacêutica ou veterinária, uso de um hidrato agente para o uso como um inibidor ou p-glicoproteìna, e, métodos para modular a mdr modulada pela p-gp no tratamento de tumores, para potencializar a citotoxicidade de um agente citotóxico para uma célula de tumor, para tratar uma doença em que o patógeno responsável exibe resistência a múltiplos medicamentos, e para realçar uma caracterìstica de um agente terapêutico - Google Patents
Processo para produzir um hidrato de um sal de adição de ácido de um composto, hidrato de um sal de adição de ácido de um composto, composição farmacêutica ou veterinária, uso de um hidrato agente para o uso como um inibidor ou p-glicoproteìna, e, métodos para modular a mdr modulada pela p-gp no tratamento de tumores, para potencializar a citotoxicidade de um agente citotóxico para uma célula de tumor, para tratar uma doença em que o patógeno responsável exibe resistência a múltiplos medicamentos, e para realçar uma caracterìstica de um agente terapêuticoInfo
- Publication number
- BR0309990A BR0309990A BR0309990-3A BR0309990A BR0309990A BR 0309990 A BR0309990 A BR 0309990A BR 0309990 A BR0309990 A BR 0309990A BR 0309990 A BR0309990 A BR 0309990A
- Authority
- BR
- Brazil
- Prior art keywords
- hydrate
- acid addition
- compound
- addition salt
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37975902P | 2002-05-14 | 2002-05-14 | |
| PCT/GB2003/002060 WO2003095447A1 (en) | 2002-05-14 | 2003-05-13 | Process for the preparation of a hydrate of an anthranilic acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309990A true BR0309990A (pt) | 2005-02-22 |
Family
ID=29420557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0309990-3A BR0309990A (pt) | 2002-05-14 | 2003-05-13 | Processo para produzir um hidrato de um sal de adição de ácido de um composto, hidrato de um sal de adição de ácido de um composto, composição farmacêutica ou veterinária, uso de um hidrato agente para o uso como um inibidor ou p-glicoproteìna, e, métodos para modular a mdr modulada pela p-gp no tratamento de tumores, para potencializar a citotoxicidade de um agente citotóxico para uma célula de tumor, para tratar uma doença em que o patógeno responsável exibe resistência a múltiplos medicamentos, e para realçar uma caracterìstica de um agente terapêutico |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7524861B2 (https=) |
| EP (1) | EP1506188B1 (https=) |
| JP (1) | JP4464814B2 (https=) |
| KR (1) | KR101060971B1 (https=) |
| CN (1) | CN100349888C (https=) |
| AT (1) | ATE423778T1 (https=) |
| AU (1) | AU2003233899B2 (https=) |
| BR (1) | BR0309990A (https=) |
| CA (1) | CA2485430C (https=) |
| DE (1) | DE60326341D1 (https=) |
| WO (1) | WO2003095447A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100557093B1 (ko) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| CA2634113A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| GB0706072D0 (en) * | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| SI2408750T1 (sl) | 2009-03-20 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2819670A1 (en) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| PE20160605A1 (es) | 2013-07-30 | 2016-07-20 | Gilead Connecticut Inc | Formulaciones de inhibidores de la syk |
| KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 다형체 |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| CN103804352B (zh) * | 2014-01-23 | 2017-06-13 | 中国药科大学 | 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| CN104327046B (zh) * | 2014-10-14 | 2017-11-17 | 中国药科大学 | 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用 |
| CN104434947B (zh) * | 2014-11-07 | 2016-11-09 | 滨州医学院附属医院 | 一种抗胆管癌的药物组合物及其应用 |
| EP3378858A1 (en) * | 2017-03-21 | 2018-09-26 | Bioprojet | Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same |
| EP3672974A1 (en) | 2017-08-25 | 2020-07-01 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
| AU2021358977A1 (en) * | 2020-10-07 | 2023-04-27 | Health Hope Pharma Hk Limited | Acetamido-phenylbenzamide derivatives and methods of using the same |
| CN112724124A (zh) * | 2021-01-18 | 2021-04-30 | 林剑雄 | 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用 |
| CN117304105A (zh) * | 2023-08-18 | 2023-12-29 | 中国科学院基础医学与肿瘤研究所(筹) | 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100220538B1 (ko) * | 1991-01-11 | 1999-09-15 | 뮈쉘 쥐르밀 | 아크리딘 유도체 |
| CN100354265C (zh) * | 1996-10-18 | 2007-12-12 | 埃克森诺瓦有限公司 | 邻氨基苯甲酸衍生物及其制备方法和作为多种抗性调节剂的用途 |
| GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
-
2003
- 2003-05-13 KR KR1020047018344A patent/KR101060971B1/ko not_active Expired - Fee Related
- 2003-05-13 CN CNB038159295A patent/CN100349888C/zh not_active Expired - Fee Related
- 2003-05-13 CA CA2485430A patent/CA2485430C/en not_active Expired - Fee Related
- 2003-05-13 WO PCT/GB2003/002060 patent/WO2003095447A1/en not_active Ceased
- 2003-05-13 US US10/513,986 patent/US7524861B2/en not_active Expired - Fee Related
- 2003-05-13 AT AT03727661T patent/ATE423778T1/de not_active IP Right Cessation
- 2003-05-13 AU AU2003233899A patent/AU2003233899B2/en not_active Ceased
- 2003-05-13 EP EP03727661A patent/EP1506188B1/en not_active Expired - Lifetime
- 2003-05-13 BR BR0309990-3A patent/BR0309990A/pt not_active IP Right Cessation
- 2003-05-13 DE DE60326341T patent/DE60326341D1/de not_active Expired - Lifetime
- 2003-05-13 JP JP2004503463A patent/JP4464814B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050009706A (ko) | 2005-01-25 |
| AU2003233899A1 (en) | 2003-11-11 |
| CA2485430A1 (en) | 2003-11-20 |
| JP2005538051A (ja) | 2005-12-15 |
| CA2485430C (en) | 2011-12-06 |
| CN100349888C (zh) | 2007-11-21 |
| DE60326341D1 (de) | 2009-04-09 |
| US20050222199A1 (en) | 2005-10-06 |
| US7524861B2 (en) | 2009-04-28 |
| WO2003095447A1 (en) | 2003-11-20 |
| KR101060971B1 (ko) | 2011-09-01 |
| EP1506188B1 (en) | 2009-02-25 |
| JP4464814B2 (ja) | 2010-05-19 |
| ATE423778T1 (de) | 2009-03-15 |
| CN1665806A (zh) | 2005-09-07 |
| EP1506188A1 (en) | 2005-02-16 |
| AU2003233899B2 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309990A (pt) | Processo para produzir um hidrato de um sal de adição de ácido de um composto, hidrato de um sal de adição de ácido de um composto, composição farmacêutica ou veterinária, uso de um hidrato agente para o uso como um inibidor ou p-glicoproteìna, e, métodos para modular a mdr modulada pela p-gp no tratamento de tumores, para potencializar a citotoxicidade de um agente citotóxico para uma célula de tumor, para tratar uma doença em que o patógeno responsável exibe resistência a múltiplos medicamentos, e para realçar uma caracterìstica de um agente terapêutico | |
| AU2020203246B2 (en) | Polymorphs of selinexor | |
| BR0309553A (pt) | Composto ou sal farmaceuticamente aceitável ou éster ou amida hidrolisável in vivo deste, processo para prepará-lo, composição farmacêutica, uso do composto, e, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, e para tratar câncer em um animal de sangue quente | |
| MX347544B (es) | Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo. | |
| PT1613315E (pt) | Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias | |
| BR0317524A (pt) | Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso | |
| BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
| DE60219954D1 (de) | Neue Indol-2-on Derivate | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| EA201001365A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ | |
| EP1867649A4 (en) | PIPERIDYL-2,6-DION DERIVATIVES USED TO INHIBIT THE RELEASE OF TUMOR NECROSIS FACTOR FROM CELLS | |
| RU2017117413A (ru) | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона | |
| BRPI0411863A (pt) | derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos | |
| CY1113270T1 (el) | Παραγωγα φουρο [3,2-β] πυρρολ-3-ονης και η χρηση τους ως αναστολεων κυστεϊνυλ πρωτεϊνασης | |
| ATE547417T1 (de) | Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten | |
| JP2020516591A (ja) | Ｍｏｒアゴニストおよびｋｏｒアゴニストを含有する医薬組成物、およびその用途 | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы | |
| WO2008023258A8 (en) | Piperidine derivatives | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
| EA201070747A1 (ru) | Фармацевтический препарат, содержащий толперизон |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: C07D 401/12, A61K 31/47, C07D 409/14, C07D 217/04, A61P 35/00 Ipc: C07D 401/12 (2011.01), A61K 31/47 (2011.01), C07D |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015. |